Fig. 5: Targeted therapy decreases average time to progression but has minimal effect on progression sequence. | Nature Communications

Fig. 5: Targeted therapy decreases average time to progression but has minimal effect on progression sequence.

From: Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer

Fig. 5

a Lung-First, Other-First and Liver-First patients overall survival stratified by treatments. b Lung-First, Other-First and Liver-First patient proportions by treatments. c–e are patient progression sequences stratified by treatments. f–h are the box plots of the first lesion progression time (1st), time between first and second progression (2nd-1st), time between second and third progression (3rd-2nd), time between third and fourth progression (4th-3rd), and the average progression time by treatments of the groups in c–e. N = 307/n = 440/n = 335 patients from TAR + Chemo and n = 270/n = 490/n = 304 patients from Chemo Alone were included in f–h. The box extends from the 25th to 75th percentiles and the line in the middle is plotted as the median. The whiskers are drawn down to the 10th percentile and up to the 90th percentile. Points below and above the whiskers represent individual lesions. P-values in f–h were calculated by two-sided Kruskal-Wallis tests. TAR + Chemo, antibody-targeted therapies (bevacizumab or panitumumab) plus chemotherapy; Chemo Alone Chemotherapy alone. Source data are provided as a Source Data file.

Back to article page